Anthony Ting
Dr. Ting has over 30 years of academic and industry experience in translational science and global regulatory filing with over 20 years in the cell therapy field. He is the Chief Commercialization Officer and on the Board of Directors for the International Society for Cell and Gene Therapy (ISCT) and serves on committees for the Alliance for Regenerative Medicine (ARM) and the Health and Environmental Sciences Institute (HESI). He is currently the Principal for BRL C> Consulting. Most recently, he served as the Chief Scientific Officer for Bone Therapeutics, a publicly traded company in Brussels, where he developed a novel induced-pluripotent stem cell platform for genetically engineered mesenchymal stem cells. Dr. Ting also served on the senior management team of Athersys, a Nasdaq-listed clinical-stage cell therapy company, as Vice President of Regenerative Medicine and Head of Cardiopulmonary Programs where he was responsible for all stages of development, from the bench to the bedside for the cardiovascular and pulmonary programs with Athersys’ most advanced cell therapy product MultiStem ® , an allogeneic adult bone marrow-derived stem cell product. Prior to joining Athersys, he was a Principal Investigator and Head of the Novel Inhibitors Screening Group at the Institute of Molecular and Cell Biology (IMCB) at the National University of Singapore, which identified new therapeutic targets through high-throughput screening. Dr. Ting had a post-doctoral fellowship at Stanford University in Molecular and Cellular Physiology and received his PhD in Cell Biology from Johns Hopkins University and his B.A. in Biology from Amherst College.
Contact information
Anthony Ting, PhD
Principal
BRL C> Consulting
Shaker Heights, OH 44122
Tel: (440) 941-4688
Also Speaking
Branden Salinas
Also Speaking
